Monday, February 19 , 2018, 10:56 am | Fair 53º

 
 
 
 

Business

MedBridge Announces Significant Investment in VG Life Sciences

MedBridge LLC, a Santa Barbara-based leading provider of management services in the health-care industry, announced Monday a significant investment and involvement in publicly traded VG Life Sciences (OTC Pink: VGLS), a biotechnology company focused on technologies for the discovery and development of drug therapies for cancer, infectious disease and inflammation.

MedBridge CEO Dave Odell
MedBridge CEO Dave Odell

“Our company was founded on the overarching principle that we help professionals be professionals in the area they are most skilled and passionate about,” MedBridge President/CEO Dave Odell said. “We believe that by taking administrative tasks off their plate, our partners can pursue leading edge advancements with even more vigor and focus. We exist so that they can focus on what they do best. What we do best is managing businesses.

“By leveraging our administrative practice, VG Life Sciences can focus on moving their important technologies forward. Our goals are simple: Make the professionals successful and thus create stockholder value.”

MedBridge’s investment in VGLS includes more than $500,000 in cash infusion, full administrative support, and representation on the VGLS Board of Directors.

“This is a transformational development for VG Life Sciences,” said Haig Keledjian, CEO of VG Life Sciences. “The significant commitment from MedBridge provides us with the capital and operational infrastructure to focus our efforts on advancing our pipeline of preclinical drug candidates into Phase I human clinical trials. Over the next two years, we expect to complete the required preclinical safety, pharmacology, and toxicity studies to move our targeted peptide technologies into Phase I clinical trials for several applications, including HIV, lyme disease and inflammatory syndromes.”

John Tynan, president of the TynanGroup Companies, who is also a longtime investor in VGLS and MedBridge partner, will also be a board member together with Odell.

“We welcome David Odell and John Tynan to our board and expect to benefit greatly from their significant business expertise,” Keledjian said. “As longtime VG Life Sciences investors, and in David’s case, by service as a board member to our majority-owned subsidiary VG Energy, these seasoned executives have fully vetted our drug pipeline and associated IP and have now paved the way for accelerated growth and increased shareholder value through their continued support.”

VGLS’ chief scientist is M. Karen Newell-Rogers, Ph.D. Dr. Newell-Rogers is primary inventor of both the Targeted Peptides and Metabolic Disruption patented technologies. She is the Raleigh R. White Jr. Endowed Professor of Surgical Research, Department of Surgery, College of Medicine, at Texas A&M Health Sciences Center and Scott and White Hospital in Temple, Texas. Newell-Rogers is also the Director of the newly formed Center for Cell Death and Differentiation at TAMHSC/Scott and White Hospital.

VGLS’ Advisory Board includes noted doctor Eric Rosenberg, M.D., associate professor of medicine Harvard Medical School. Dr. Rosenberg has an extensive background studying HIV. He is best known for his research on early HIV infection. VGLS’ peptide platform is a targeted application for HIV.

— Alex Sumner represents MedBridge.

  • Ask
  • Vote
  • Investigate
  • Answer

Noozhawk Asks: What’s Your Question?

Welcome to Noozhawk Asks, a new feature in which you ask the questions, you help decide what Noozhawk investigates, and you work with us to find the answers.

Here’s how it works: You share your questions with us in the nearby box. In some cases, we may work with you to find the answers. In others, we may ask you to vote on your top choices to help us narrow the scope. And we’ll be regularly asking you for your feedback on a specific issue or topic.

We also expect to work together with the reader who asked the winning questions to find the answer together. Noozhawk’s objective is to come at questions from a place of curiosity and openness, and we believe a transparent collaboration is the key to achieve it.

The results of our investigation will be published here in this Noozhawk Asks section. Once or twice a month, we plan to do a review of what was asked and answered.

Thanks for asking!

Click here to get started >

Support Noozhawk Today

You are an important ally in our mission to deliver clear, objective, high-quality professional news reporting for Santa Barbara, Goleta and the rest of Santa Barbara County. Join the Hawks Club today to help keep Noozhawk soaring.

We offer four membership levels: $5 a month, $10 a month, $25 a month or $1 a week. Payments can be made through PayPal below, or click here for information on recurring credit-card payments.

Thank you for your vital support.



Reader Comments

Noozhawk is no longer accepting reader comments on our articles. Click here for the announcement. Readers are instead invited to submit letters to the editor by emailing them to [email protected]. Please provide your full name and community, as well as contact information for verification purposes only.

Daily Noozhawk

Subscribe to Noozhawk's A.M. Report, our free e-Bulletin sent out every day at 4:15 a.m. with Noozhawk's top stories, hand-picked by the editors.

Sign Up Now >

Meet Your Realtor Sponsored by Village Properties


Dianne and Brianna Johnson
"We are committed to making our clients feel special by providing the concierge level service they deserve."

Full Profile >